Financial statements Relyonart Biotech Investment Fund
Balance sheet of Relyonart Biotech Investment Fund
Company age:
Age:
3 y. 21 d.
Share capital:
Share capital:
2 081 000 PLN
Balance sheet data of RELYONART BIOTECH INVESTMENT FUND
|
Year
|
2021
|
2022
|
2022
|
2023
|
|---|---|---|---|---|
| Total assets | 3 867 738,26 | 3 862 734,51 | 3 859 830,31 | 3 840 015,71 |
| A. Fixed assets | 2 162 720,00 | 2 162 720,00 | 2 162 720,00 | 2 220 053,33 |
| B. Current assets | 1 705 018,26 | 1 700 014,51 | 1 697 110,31 | 1 619 962,38 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 3 867 738,26 | 3 862 734,51 | 3 859 830,31 | 3 840 015,71 |
| A. Equity | 3 796 415,97 | 3 778 585,17 | 3 777 025,97 | 3 768 582,72 |
| B. Liabilities and provisions for liabilities | 71 322,29 | 84 149,34 | 82 804,34 | 71 432,99 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 70 322,29 | 83 649,34 | 81 804,34 | 70 432,99 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.